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Abstract
Background: Disruption of alternative splicing in apoptotic factors has been associated to chronic lymphocytic
leukemia among other cancers and hematological malignancies. The proapoptotic proteins Caspase-9 and PP2Acα
are functionally related in a direct interaction, which constitutes a promising target for cancer therapy. Both
proteins present aberrant mRNA splicing variants that are antiapoptotic (Caspase-9b) and catalytically inactive
(PP2Acα2), respectively.
Results: In this work we have analyzed the relative abundance of the aberrant spliced forms Caspase-9b and
PP2Acα2 in several cell lines and chronic lymphocytic leukemia patients and correlated it with several parameters of
the disease. Despite 40 % of the patients presented Caspase-9b dysregulation, there was no direct association
between alterations in Caspase-9b relative abundance and the parameters analyzed in medical records. More
importantly, PP2Acα2 dysregulation was observed in 88 % of CLL patients and was related with advanced stages of
the malignancy.
Conclusions: Caspase-9b dysregulation seemed to be associated with the disease, although the differences
between healthy donors and CLL patients were not statistically significant. However, PP2Acα2 dysregulation was
significantly different between healthy donors and CLL patients and correlated with Binet B and C stages; therefore,
we propose the use of PP2Acα2 dysregulation as a potential biomarker for advanced stages of chronic lymphocytic
leukemia.
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Introduction
Chronic lymphocytic leukemia (CLL) is the most common
B-cell malignancy in Caucasian aging adults, rarely younger
than 50 years old [1]. Disruption of alternative splicing in
many apoptotic factors is related to hematological malig-
nancies and cancer, as CLL [2–6]. Abnormally expressed
splicing factors in tumor cells induce the production of
mRNA isoforms that are nonexistent or less abundant in
normal cells, thus contributing to cancer development,
tumor progression, different response to therapy and che-
morefractoriness [7, 8].
Caspase-9 is a key point in the apoptotic signal transduc-
tion. The expression of its mRNA spliced variant Caspase-
9b, lacking exons 3 to 6, inhibits apoptosis in a dominant-
negative manner [9], which may establish a threshold to
regulate Caspase-9 activation and prevent undesired apop-
tosis [10]. Caspase-9b is dysregulated in astrocytoma [11]
and in several subtypes of non-small-cell lung cancer
(NSCLC). Moreover, its overexpression was responsible of
maintaining the tumorigenic capacity of NSCLC cells and
made cells resistant to erlotinib [12]. Targeting the
alternative splicing of Caspase-9 sensitized NSCLC cells to
chemotherapies, increasing their efficiency and limiting
their toxic side-effects [13].
The direct interaction between Caspase-9 and PP2Acα
has been previously described [14]. PP2A is one of the
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major Ser/Thr phosphatases, whose dysregulation is as-
sociated with multiple cancers among other functions
[15]. A catalytically inactive aberrant isoform of PP2A
catalytic C subunit, PP2Acα2, has been reported, missing
exon 5, which is close to the active site. PP2Acα2 has
only been observed overexpressed in peripheral blood
mononuclear cells (PBMC) under starvation conditions
but the ratio PP2Acα:PP2Acα2 was reestablished once
they were transferred to culture medium. When ana-
lyzed in cell lines, PP2Acα2 was present either as mRNA
or as protein but at almost undetectable levels [16].
The aim of the present work was to study the ex-
pression ratios Caspase-9: Caspase-9b and PP2Acα:P-
P2Acα2 in cell lines and more importantly in healthy
donors and CLL patients to evaluate their association
with the disease.
Material and methods
Cell lines culture
HeLa cells were cultured in DMEM + 10 % FBS,
Daudi and Jurkat cells in RPMI 1640 + 10 % FBS and
SH-SY5Y in DMEM F12 + 10 % FBS, 1 % Glutamine
and 1 % Hepes 1 M. All cell lines were grown at
37 °C and 5 % CO2 and underwent passage three
times a week.
B cells isolation
Fresh blood from healthy donors was obtained from
the Établissement français du sang. CLL samples were
obtained from the Hematology Department of Saint
Louis hospital (Paris). PBMC were isolated by Ficoll
gradient centrifugation for 20 min at 2300 rpm, they
were collected and washed twice with PBS. B cells
were isolated using DynaI negative isolation kit (Invi-
trogen), reaching around 98 % purity.
Conventional PCR and Real Time PCR
Total RNA was extracted with TRIzol® (Life Technolo-
gies), cDNA was obtained performing RT-PCR using High
Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems) and conventional PCR was set up with Kapa HiFi
DNA polymerase (Kapa Biosystems) at 95 °C-3’, 30 cycles
of 98 °C-20”, 55 °C-20”, 72 °C-1’30” and a final extension
of 72 °C-5’. The primers used were FWD: 5’-ATGGAC-
GAAGCGGATCGG-3’ and REV: 5’-TTATGATGTTT-
TAAAGAAAAGTT-3’ for Caspase-9 and FWD 5’-
GACGAGAAGGTGTTCACCAA-3’ and REV 5’-TTA-
CAGGAAGTAGTCTGGGGTAC-3’ for PP2Acα.
Real Time PCR was performed using TaqMan PCR
Mastermix in a 7500 Fast Real Time Applied Biosystems
device. Caspase9 and PP2Acα probes corresponded to
Hs00154261_m1 and Hs01003394_mH Life Technolo-
gies references. Caspase9b probe was previously de-
scribed [17] and PP2Acα2 primers and probe were
designed: 5’-CAAGAAGTTCCCCATGAGGGATATA-3’
(forward), 5’-CAACGATAACAATAGTTTGGAGCACT-
3’ (reverse) and 5’-CGTTACTACATTCCGGTCATGG-
CACCA-3’ (probe). GAPDH was used as housekeeping
reference gene (Hs99999905_m1, Life Technologies).
Data analysis of relative expression was calculated
following the 2-ΔΔCT method [18]. Differences between
healthy donors and CLL patients were statistically evalu-
ated with Student's t test and with a Two-way ANOVA
with replication with a significance level of P < 0.005.
Results and discussion
Caspase-9b and PP2Acα2 expression in cell lines
Among the cell lines analyzed, derived from different
oncologic malignancies, all of them showed a healthy
ratio of Caspase-9b relative abundance in PCR and Real
Time PCR assays (Fig. 1a and b). As established by
Shultz et al. [19], the criteria used to classify Caspase-9b
Fig. 1 Analysis of Caspase-9b and PP2Acα2 in several cancer cell lines. a. Conventional PCR analysis of cancer cell lines showing Caspase-9 and
PP2Acα full length and spliced variants expression. b. Real Time PCR of cancer cell lines. Caspase-9b and PP2Acα2 relative abundance is repre-
sented in the graph and normalized with respect to Caspase-9 and PP2Acα respectively, considered as 1
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levels were: normal (Caspase-9: Caspase-9b mRNA ratio
≥3.3), moderately dysregulated (3.3 > X > 2.2) and highly
dysregulated (≤2.2). Following the criteria that we
established for CLL patients as described below, cell
lines possessed PP2Acα2 mRNA levels corresponding
to healthy state, obtaining very low values in Real
Time PCR and a faint band in conventional PCR,
when detected (Fig. 1a and b). These results suggest
that Caspase-9b or PP2Acα2 dysregulation wouldn’t
be characteristic of the analyzed cell lines, which
prompted us to consider the approach of using sam-
ples from CLL patients instead of insisting with other
established cell lines. Patients samples of these path-
ologies should be analyzed to confirm cell lines data;
nevertheless in previous studies Caspase-9b dysregula-
tion has been observed in the same extent in NSCLC
cells and patients [12].
Caspase-9b and PP2Acα2 expression in healthy donors
and CLL patients
Conventional PCR showed that Caspase-9b was slightly
expressed in healthy donors, while CLL patients showed
a moderate overexpression. Healthy donors showed no
detectable or very low expression of PP2Acα2, but the
majority of CLL patients presented from moderate to
high overexpression of the aberrant form (Fig. 2a).
A cohort of 24 healthy donors and 25 CLL patients (15
men and 10 women) was analyzed by Real Time PCR.
Figure 2b summarizes Caspase-9b and PP2Acα2 expres-
sion in CLL patients. 80 % of healthy donors showed
Caspase-9b normal ratio and the rest were slightly over
healthy values (Fig. 2c). Unlike in NSCLC [19], where
36 % of the patients were moderately dysregulated and
42 % were highly dysregulated, in CLL only 40 % of the
patients had some alteration in Caspase-9b expression
(Fig. 2d), although the highly dysregulated also overcame
the moderate percentage (28 % versus 12 %).
According to Shultz et al.[19] criteria for Caspase-
9b dysregulation, 80 % of the healthy donors that we
analyzed fitted into normal values for Caspase-9b.
However, PP2Acα2 was expressed in healthy donors
in a PP2Acα:PP2Acα2 ratio from negligible values up
to 1.27 in 80 % of the samples (Fig. 2c). Therefore,
we formulated classification criteria that would fit a
similar percentage of healthy donors in each cat-
egory as the ones described by Schultz for Caspase-
9b. We established a mRNA ratio PP2Acα:PP2Acα2 ≥
1.33 for healthy expression, 0.67 < X < 1.33 for mod-
erately dysregulated and ≤ 0.67 for highly dysregu-
lated. According to this, 88 % of CLL patients
analyzed had overexpression levels of PP2Acα2
(Figs. 2b and d). The efficacy of the use of PP2Acα2
as a CLL biomarker and the applicability of our cri-
teria was validated with the calculation of several
clinical parameters. The prevalence of the disease in
the whole cohort was 51.02 % and the use of
PP2Acα2 as a biomarker presented a sensitivity of
78.57 %, a specificity of 85.71 %, a positive predictive
value of 88 % and a negative predictive value of
75 %. According to these results, the detection of a
PP2Acα2 overexpression in a patient will allow to
diagnose CLL in a 78.57 % of the cases. The specifi-
city of this biomarker assures that 85.71 % of the
patients without a dysregulation of PP2Acα2 don’t
present the disease and only a 14.29 % would be di-
agnosed as false positives.
Gathering the data of relative abundance of spliced
variants with the medical records available [20, 21]
(Table 1), we couldn’t establish a direct correlation
between the dysregulation in Caspase-9b and any of
the disease parameters analyzed, but we don’t exclude
that it may be related to other features of this malig-
nancy. However, this dysregulation in 40 % of CLL
patients makes us consider it as a manifestation of
the disease and it could be a potential biomarker in
some extent, although the differences between healthy
donors and CLL patients were not statistically signifi-
cant according to Student’s t test (P = 0.1878). Inter-
estingly, all individuals classified in the medical
records as B or C Binet score [20] presented highly
dysregulated PP2Acα2, being the only patient with
score C the one with the highest PP2Acα2 levels.
Among A score patients, PP2Acα2 levels from normal
to highly dysregulated were found. In this case, the
differences between healthy donors and CLL patients
for PP2Acα2 relative abundance were statistically sig-
nificant (P < 0.005, P = 0.0024). A two-way ANOVA
with replication was also performed between healthy
donors and CLL patients 1–24 for Caspase-9b and
PP2Acα2 relative abundance. The differences between
healthy donors and CLL patients were significant (P <
0.0005) and also between Caspase-9b and PP2Acα2
(P < 0.00005). The interaction P-value (P < 0.005) sug-
gested that the variables Caspase-9b and PP2Acα2 are
different depending on the level of the other variable
respectively. The distribution of Caspase-9b and
PP2Acα2 relative abundance in the healthy donors
and CLL patients populations was represented in
Fig. 3. Although more extensive studies should be
performed to confirm these data, we have promising
evidences that suggest the importance of PP2Acα2 in
the course of CLL. For the first time, the aberrant
spliced variant PP2Acα2 has been related with a
pathological state, suggesting its implication in the
disease and a possible function for a protein that re-
mains known as inactive.
Several markers as CD38, ZAP-70 and IgVH mutation
status among others have been implemented as CLL
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Fig. 2 Analysis of Caspase-9b and PP2Acα2 in healthy donors and CLL patients. a. Conventional PCR analysis of three healthy donors and
three CLL patients for Caspase-9 and PP2Acα full length and spliced variants expression. b. Percentage of CLL patients that present
normal, moderately dysregulated and highly dysregulated relative abundance of Caspase-9b and PP2Acα2. c. Real Time PCR analysis of
healthy donors. Relative abundance values of spliced forms have been normalized with respect to full length forms, considered as 1.
The limits for moderately dysregulated values are marked with a grey dotted line and the limits for highly dysregulated values with a
black dotted line. d. Real Time PCR analysis of CLL patients. The same criteria as for Fig. 2c were applied for calculations and limits
representation. Asterisk represents P < 0.005 (P = 0.0024), when compared with healthy donor
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progression and diagnosis predictors not without certain
controversy [22–24]; therefore we propose also the use
of PP2Acα2 high dysregulation as a potential CLL bio-
marker associated to severe stages of the disease.
Disruption of the PP2Acα:PP2Acα2 ratio in CLL pa-
tients may also alter the equilibrium of Caspase-9/PP2Acα
interaction, giving rise to aberrant Caspase-9/PP2Acα2
complexes. Interestingly, we have previously reported a bi-
functional peptide termed DPT-C9h, capable of dissociat-
ing Caspase-9/PP2Acα complex [14]. Given that Caspase-
9 binding site is present in both PP2Acα and PP2Acα2,
DPT-C9h may also interfere in the hypothetical Caspase-
9/PP2Acα2 interaction, contributing to a possible modula-
tion of the DPT-C9h mechanism of action and differential
treatment response [14].
This bifunctional peptide induced apoptosis in CLL B
cells without affecting healthy B cells nor the rest of per-
ipheral blood mononuclear cells [25]. The bifunctional
peptide DPT-C9h was also capable of inducing apoptosis
in several cancer cell lines and in tumor xenograft
models with treatment response in a different extent,
which may be related to the relative abundance of
PP2Acα2 in the cell lines and patients tested [14]. Fur-
ther experiments will be performed to shed light on the
role of PP2Acα2 in CLL and the hypothetical differential
response to DPT-C9h depending on the level of PP2Acα2
dysregulation.
Caspase-9b has been related to disease state in astrocy-
toma [11] and to play an important role in NSCLC treat-
ment response [12]. Our results provide first evidences for
Table 1 Available medical records of the CLL patients analyzed
Patient Age at diagnosis Previous treatments White blood cells Hemoglobin Platelets Matutes score Binet score Caspase-9b PP2Acα2
CLL15 71 NO 100000 10.2 86 4 C 0.05 11.93
CLL13 56 NO 97000 11.7 230 5 B 0.05 5.73
CLL12 63 NO 85000 12.7 116 5 B 0.10 3.96
CLL21 64 NO 110000 9.8 95 5 B 0.13 3.80
CLL6 82 NO 28000 10.6 206 5 B 0.57 3.74
CLL19 60 YES 230000 12.5 90 5 B 0.09 2.26
CLL5 72 NO 200000 12.9 92 5 A 1.90 3.68
CLL2 78 NO 100000 12.3 223 4 A 0.55 2.19
CLL1 50 NO 130000 10.9 189 5 A 1.34 1.89
CLL20 68 NO 87000 10.6 120 5 A 0.12 1.87
CLL16 43 NO 44000 15.0 210 5 A 0.06 1.38
CLL11 75 NO 25000 14.2 186 4 A 0.14 1.24
CLL4 72 NO 27000 14.6 250 5 A 1.30 1.02
CLL3 68 NO 80000 13.1 188 5 A 0.83 0.82
CLL17 87 NO 140000 10.1 66 5 A 0.11 0.38
Age, treatment with fludarabin (in the case of CLL19), hematological parameters and Matutes score (that confirms these patients as CLL) registered in medical
records for some of the patients analyzed are compiled in this table. Binet score B and C, indicating advanced stages of the disease, are highlighted in bold.
Normalized values of relative abundance of Caspase-9b and PP2Acα2 have been added to the table
Fig. 3 Normalized relative abundance of Caspase-9b and PP2Acα2 in healthy donors and CLL patients populations. Second quartile is represented
in grey and third quartile in black. Maximums and minimums are shown with error bars
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the presence of aberrant PP2Acα/PP2Acα2 ratios in CLL
advanced stage patients. Therefore, the dysregulation of
the splicing variants of the association Caspase-9/PP2Acα
is emerging as a valuable tool as biomarkers for prognosis
in cancers that present aberrant expression of Caspase-9b
or PP2Acα2 spliced variants. Further studies will need to
be performed to evaluate Caspase-9/Caspase-9b and
PP2Acα/PP2Acα2 ratios in other types of cancer and their
possible application as biomarkers.
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